Stockscreener 앱 받기
6.38
11.14%
-0.80
시간 외 거래:
6.38
전일 마감가:
$7.18
열려 있는:
$6.64
하루 거래량:
2.24M
Relative Volume:
1.77
시가총액:
$327.12M
수익:
$676.80M
순이익/손실:
$-8.60M
주가수익비율:
-22.55
EPS:
-0.2829
순현금흐름:
$135.40M
1주 성능:
-9.63%
1개월 성능:
-5.48%
6개월 성능:
-25.99%
1년 성능:
-32.13%
1일 변동 폭
$6.1505
$6.73
1주일 범위
$6.1505
$7.33
52주 변동 폭
$4.36
$14.06
Emergent Biosolutions Inc Stock (EBS) Company Profile
명칭
Emergent Biosolutions Inc
전화
240-631-3200
주소
300 PROFESSIONAL DR, GAITHERSBURG, MD
Compare EBS vs TAK, TEVA, HLN, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
6.38 | 327.12M | 676.80M | -8.60M | 135.40M | -0.2829 |
TAK
Takeda Pharmaceutical Co Adr
|
19.67 | 62.84B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.50 | 48.40B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
10.13 | 44.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.38 | 32.80B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
533.12 | 22.87B | 3.17B | 1.29B | 1.01B | 27.09 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-08-21 | 재개 | JP Morgan | Underweight |
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-22 | 개시 | Rodman & Renshaw | Buy |
| 2024-03-07 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-11-20 | 재개 | JP Morgan | Underweight |
| 2023-08-29 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-04-10 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-03-17 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-11-10 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2022-04-29 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2022-01-20 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-11-08 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-05-05 | 다운그레이드 | Argus | Buy → Hold |
| 2021-04-07 | 개시 | The Benchmark Company | Buy |
| 2021-02-24 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2021-02-19 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2021-01-08 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-09-14 | 재개 | JP Morgan | Neutral |
| 2020-07-31 | 재확인 | Chardan Capital Markets | Buy |
| 2019-09-12 | 개시 | Guggenheim | Buy |
| 2019-09-04 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2018-11-02 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-08-03 | 재확인 | Chardan Capital Markets | Buy |
| 2018-06-13 | 개시 | Argus | Buy |
| 2018-04-25 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2018-01-16 | 재확인 | Chardan Capital Markets | Buy |
| 2016-06-28 | 재확인 | Singular Research | Buy |
| 2016-04-15 | 개시 | Chardan Capital Markets | Buy |
| 2016-03-28 | 개시 | Singular Research | Buy |
| 2016-02-19 | 개시 | Wells Fargo | Outperform |
| 2014-05-15 | 개시 | Summer Street Research | Buy |
| 2011-05-31 | 재확인 | WBB Securities | Strong Buy |
| 2011-01-10 | 재확인 | Wedbush | Outperform |
| 2010-11-05 | 재확인 | Wedbush | Outperform |
| 2010-08-18 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2010-08-06 | 재확인 | Caris & Company | Buy |
모두보기
Emergent Biosolutions Inc 주식(EBS)의 최신 뉴스
Emergent BioSolutions stock falls as CFO plans retirement - Investing.com
Emergent BioSolutions CFO to retire, treasurer named interim - Investing.com
Emergent BioSolutions Inc. Announces Chief Financial Officer Changes - marketscreener.com
Emergent BioSolutions (EBS) CFO Richard Lindahl to Retire, Shares Drop Premarket - GuruFocus
Emergent Biosolutions Announces Retirement of Richard S. Lindahl as Executive Vice President, Effective December 31, 2026 - www.marketscreener.com
Emergent BioSolutions CFO Richard Lindahl to Retire, Frank Vargo Named Interim Successor - citybiz
Emergent BioSolutions (EBS) CFO Richard Lindahl to Retire; Inter - GuruFocus
Emergent BioSolutions CFO Richard Lindahl to retire end of 2026 - StreetInsider
Emergent BioSolutions Announces Retirement of Chief Financial Officer Richard S. Lindahl - Business Wire
Press Release: Emergent BioSolutions to Report Third Quarter 2026 Financial Results on November 2, 2026 - Moomoo
Emergent BioSolutions to Report Third Quarter 2026 Financial Results on November 2, 2026 - Business Wire
Emergent BioSolutions Director Donald W. DeGolyer Sells 17,800 Shares on October 7, 2026 - Kalkine Media
Form 4 Emergent Biosolutions Inc For: 7 October By Investing.com - Investing.com Canada
Emergent BioSolutions director DeGolyer sells $126k in shares - Investing.com
Director Donald DeGolyer proposes selling 17,800 Emergent BioSolutions (NYSE: EBS) shares. - Stock Titan
To cover stock-award taxes, an Emergent BioSolutions (EBS) director sold 17,800 shares under a trading plan. - Stock Titan
EBS5025998 Bond Profile: Coupon and Redemption - TradingView
Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock? - Zacks Investment Research
Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock? - Yahoo Finance
Form 4 Emergent Biosolutions Inc For: 5 October By Investing.com - Investing.com South Africa
Emergent BioSolutions (EBS) SVP, Products Business Paul Williams Sells 3,000 Shares - GuruFocus
Why is Emergent Biosolutions stock surging today? - Investing.com
Emergent BioSolutions stock gains 7.11 percent on October 5 - AD HOC NEWS
Emergent BioSolutions SVP Paul Williams sells $19,590 in stock - Investing.com
Form 4 Emergent Biosolutions Inc For: 5 October By Investing.com - Investing.com UK
Under a trading plan, Emergent BioSolutions (EBS) officer Williams sold 3,000 shares at $6.53. - Stock Titan
Emergent BioSolutions Inc. Common Stock (NYSE:EBS) Detailed Stock Data - The Chronicle-Journal
A 3,000-share sale is proposed by Emergent BioSolutions (EBS) officer Paul Williams. - Stock Titan
Emergent BioSolutions Inc. (EBS) Investigation: Bronstein, Gewirt - The National Law Review
Precision Trading with Emergent Biosolutions Inc. (EBS) Risk Zones - news.stocktradersdaily.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc.EBS - PR Newswire
Emergent BioSolutions Inc (ER4.DU) Analyst insights, Price targets and RecommendationsYahoo Finance - Yahoo Finance Singapore
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc.EBS - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc.EBS - FinancialContent
Emergent BioSolutions stock steady as investors weigh recent fundamentals - AD HOC NEWS
Emergent BioSolutions Inc. (EBS) Stock Analysis: Unpacking A 56.7% Potential Upside - DirectorsTalk Interviews
Emergent BioSolutions restarts Massachusetts manufacturing after $34.5M vaccine deal - The Business Journals
Emergent BioSolutions presents transformation update, Q2 results, $40M restructuring savings and revised FY26 guidance - TradingView
Intravenous Immunoglobulin Market Size Worth USD 30.83 Billion by 2035, Growing at 7.49% CAGR – SNS Insider - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc.EBS - GlobeNewswire Inc.
Emergent Biosolutions Inc (EBS) Fundamental & Financial Data - Stocktwits
Emergent BioSolutions: Tough 2026 Outlook Warrant Rating Downgrade (NYSE:EBS) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Encourages Emergent BioSolutions Inc. (EBS) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Emergent Biosolutions Stock Price Forecast. Should You Buy EBS? - StockInvest.us
Bronstein, Gewirtz & Grossman, LLC Encourages Emergent BioSolutio - The National Law Review
Emergent BioSolutions repurchases $75 million in senior notes By Investing.com - Investing.com South Africa
Bronstein, Gewirtz & Grossman, LLC Is Investigating Emergent BioSolutions Inc. (EBS) And Encourages Shareholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Emergent BioS - The National Law Review
Emergent BioSolutions repurchases $75 million in senior notes By Investing.com - Investing.com Australia
Emergent BioSolutions Repurchases $75 Million of Debt at Discount - citybiz
Emergent Biosolutions Inc (EBS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Emergent Biosolutions Inc 주식 (EBS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| DeGolyer Donald W | Director |
Oct 07 '26 |
Sale |
7.09 |
17,800 |
126,202 |
111,921 |
| Williams Paul Anthony | SVP, Products Business |
Oct 01 '26 |
Sale |
6.53 |
3,000 |
19,590 |
156,098 |
| PAUL WILLIAMS | Officer |
Oct 01 '26 |
Proposed Sale |
6.53 |
3,000 |
19,592 |
0 |
| Williams Paul Anthony | SVP, Products Business |
Jul 01 '26 |
Sale |
8.40 |
3,000 |
25,200 |
159,098 |
| PAUL WILLIAMS | Officer |
Jul 01 '26 |
Proposed Sale |
8.40 |
3,000 |
25,205 |
0 |
| DeGolyer Donald W | Director |
May 01 '26 |
Sale |
8.40 |
15,481 |
129,994 |
129,721 |
| Zoon Kathryn C | Director |
May 01 '26 |
Sale |
8.40 |
17,202 |
144,453 |
79,941 |
| SUJATA TYAGI DAYAL | Director |
May 01 '26 |
Proposed Sale |
8.40 |
13,761 |
115,612 |
0 |
| KATHRYN ZOON | Director |
May 01 '26 |
Proposed Sale |
8.40 |
17,202 |
144,492 |
0 |
| DONALD DEGOLYER | Director |
May 01 '26 |
Proposed Sale |
8.40 |
15,481 |
130,064 |
0 |
3.06%
자본화:
|
볼륨(24시간):